{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:16:04Z","timestamp":1791404164378,"version":"4.3.3"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>SB11 and reference ranibizumab (RBZ) are monoclonal anti\u2013vascular endothelial growth factor (VEGF)\u2013A antibodies approved for the treatment of neovascular age-related macular degeneration (nAMD) and other retinal diseases. The association of ranibizumab immunogenicity and treatment outcomes in patients with nAMD is unclear but relevant regarding concerns about immunogenicity of anti-VEGF biological products.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the association of immunogenicity to ranibizumab products (SB11 and RBZ) with efficacy, safety, and pharmacokinetics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a post hoc analysis of a randomized, double-masked, parallel-group phase 3 equivalence study with participants from 75 centers in 9 countries conducted from March 14, 2018, to December 9, 2019. Included were participants 50 years or older with nAMD and active subfoveal choroidal neovascularization lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Intravitreal injection of SB11 or RBZ, 0.5 mg, every 4 weeks through week 48.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Serum antidrug antibodies (ADAs) were analyzed during the study period until week 52 to measure immunogenicity. Analyses were performed on immunogenicity (overall ADA positivity) with best-corrected visual acuity (BCVA) and central subfield thickness (CST). Adverse events associated with intraocular inflammation (IOI) and serum ranibizumab levels were compared between overall ADA-positive and ADA-negative participants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 705 participants (mean [SD] age, 74.1 [8.5] years; 403 female individuals [57.2%]) were included in the study. The overall incidence of ADA-positivity was 32 of 657 (4.9%) at week 52. The least-squares mean (SE) differences between overall ADA-positive and ADA-negative participants up to week 52 for BCVA and CST, respectively, were 1.6 (2.2) letters (95% CI, \u22122.7 to 5.8; <jats:italic>P<\/jats:italic>\u2009=\u2009.46) and 3 (13) \u03bcm (95% CI, \u221223 to 29; <jats:italic>P<\/jats:italic>\u2009=\u2009.83). IOI-related events occurred in 1 of 32 overall ADA-positive participants (3.1%) and 4 of 620 overall ADA-negative participants (0.6%). Mean (SD) serum ranibizumab concentrations over time were slightly lower in overall ADA-positive participants compared with those of ADA-negative participants, with a maximum value of 1389.3 (875.4) pg\/mL at week 16 vs 1665.4 (1124.0) pg\/mL at week 36, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Results of this post hoc analysis of an equivalence trial suggest that immunogenicity was not associated with efficacy and safety of SB11 and RBZ in participants with nAMD. With a low overall ADA incidence, no clear association was identified between overall ADA positivity and pharmacokinetics. These findings support the biosimilarity of SB11 and RBZ, with no safety concern identified for SB11 vs RBZ associated with immunogenicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03150589\">NCT03150589<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2022.5403","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T16:01:11Z","timestamp":1671120071000},"page":"117","source":"Crossref","is-referenced-by-count":38,"title":["Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics"],"prefix":"10.1001","volume":"141","author":[{"given":"Neil M.","family":"Bressler","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Editor, JAMA Ophthalmology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taehyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Samsung Bioepis, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkyung","family":"Oh","sequence":"additional","affiliation":[{"name":"Samsung Bioepis, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Russo","sequence":"additional","affiliation":[{"name":"Samsung Bioepis, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy Yeeun","family":"Kim","sequence":"additional","affiliation":[{"name":"Samsung Bioepis, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"eoi220078r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern.","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi220078r2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges.","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself"},{"key":"eoi220078r3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/issn.1421-5721","article-title":"The immunogenicity of biologic therapies.","volume":"53","author":"Garc\u00eas","year":"2018","journal-title":"Curr Probl Dermatol"},{"issue":"3","key":"eoi220078r4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"issue":"2","key":"eoi220078r5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy.","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS J"},{"issue":"1","key":"eoi220078r6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1586\/eci.10.90","article-title":"Acute infusion reactions induced by monoclonal antibody therapy.","volume":"7","author":"Maggi","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"eoi220078r8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.dmpk.2018.11.004","article-title":"Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.","volume":"34","author":"Ishii-Watabe","year":"2019","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"eoi220078r9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40259-019-00377-y","article-title":"Evolution of the EU biosimilar framework: past and future.","volume":"33","author":"Wolff-Holz","year":"2019","journal-title":"BioDrugs"},{"key":"eoi220078r10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biologicals.2020.02.005","article-title":"The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019.","volume":"65","author":"Kang","year":"2020","journal-title":"Biologicals"},{"key":"eoi220078r11","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2147\/OPTH","article-title":"Biosimilars in ophthalmology: \u201cis there a big change on the horizon?\u201d.","volume":"12","author":"Sharma","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"eoi220078r15","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319637","article-title":"Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III andomized clinical trial outcomes.","author":"Bressler","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"eoi220078r21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","article-title":"Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial.","volume":"139","author":"Woo","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"eoi220078r23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.biologicals.2015.06.004","article-title":"Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility.","volume":"43","author":"Wadhwa","year":"2015","journal-title":"Biologicals"},{"issue":"9","key":"eoi220078r25","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":"A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi220078r27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1089\/jop.2015.0152","article-title":"A prospective masked clinical assessment of inflammation after intravitreal injection of ranibizumab or aflibercept.","volume":"32","author":"Khanani","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"eoi220078r28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review.","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retina Vitreous"},{"issue":"11","key":"eoi220078r29","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/s41433-022-02117-z","article-title":"Fear of safety compromise with biosimilar anti-VEGF perception or truth.","volume":"36","author":"Sharma","year":"2022","journal-title":"Eye (Lond)"},{"issue":"10","key":"eoi220078r30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab.","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi220078r31","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER.","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"eoi220078r32","doi-asserted-by":"publisher","DOI":"10.1111\/aos.v100.8","article-title":"Antidrug antibodies to brolucizumab and ranibizumab in serum and vitreous of patients with ocular disease.","author":"Busch","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"eoi220078r34","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach.","volume":"54","author":"Xu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"eoi220078r35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration.","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"key":"eoi220078r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100862","article-title":"Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections.","volume":"80","author":"Melo","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"eoi220078r38","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41433-019-0636-3","article-title":"Ophthalmic biosimilars and biologics\u2014role of endotoxins.","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"eoi220078r7","unstructured":"Samsung Bioepis. BYOOVIZ (ranibizumab-nuna) US prescribing information. Accessed April 7, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761202Orig1s000lbl.pdf"},{"key":"eoi220078r12","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. Accessed March 24, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf"},{"key":"eoi220078r13","unstructured":"US Food & Drug Administration. Biosimilar development, review, and approval. Accessed March 13, 2022. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-development-review-and-approval"},{"key":"eoi220078r14","unstructured":"US Food & Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Accessed March 24, 2020. https:\/\/www.fda.gov\/media\/82647\/download"},{"key":"eoi220078r16","unstructured":"Samsung Bioepis. Byooviz (ranibizumab) EU summary of product characteristics. Accessed March 16, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/byooviz-epar-product-information_en.pdf"},{"key":"eoi220078r17","unstructured":"US Food & Drug Administration (FDA). FDA approves first biosimilar to treat macular degeneration disease and other eye conditions. Accessed June 3, 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-biosimilar-treat-macular-degeneration-disease-and-other-eye-conditions"},{"key":"eoi220078r18","unstructured":"Genentech. Lucentis (ranibizumab injection) US prescribing information. Accessed March 16, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125156s105lbl.pdf"},{"key":"eoi220078r19","unstructured":"European Medicines Agency. Byooviz (ranibizumab) European public assessment report. Accessed April 7, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/byooviz-epar-public-assessment-report_en.pdf"},{"key":"eoi220078r20","unstructured":"A study to compare SB11 (proposed ranibizumab biosimilar) to Lucentis in subjects with neovascular age-related macular degeneration (AMD). ClinicalTrials.gov identifier: NCT03150589. Updated May 21, 2021. Accessed June 8, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03150589"},{"key":"eoi220078r22","unstructured":"US Food & Drug Administration. Immunogenicity testing of therapeutic protein products\u2014developing and validating assays for antidrug antibody detection. Accessed March 15, 2022. https:\/\/www.fda.gov\/media\/119788\/download"},{"key":"eoi220078r24","unstructured":"Novartis. Lucentis (ranibizumab) EU summary of product characteristics. Accessed June 3, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lucentis-epar-product-information_en.pdf"},{"key":"eoi220078r26","unstructured":"US Food & Drug Administration. Lucentis (Ranibizumab) injection\u2014medical review(s). Accessed June 17, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/125156s0000_Lucentis_MedR.pdf"},{"key":"eoi220078r33","unstructured":"FDA Center for Drug Evaluation and Research. Biologics license application for brolucizumab-dbll\u2014summary review. Accessed June 6, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761125Orig1s000SumR.pdf"},{"key":"eoi220078r36","unstructured":"European Medicines Agency. Guideline on immunogenicity assessment of therapeutic proteins. Accessed April 11, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf"},{"key":"eoi220078r39","unstructured":"European Medicines Agency. Biosimilars in the EU\u2014information guide for health care professionals. Accessed April 11, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2799737\/jamaophthalmology_bressler_2022_oi_220078_1675440850.86531.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T16:02:22Z","timestamp":1676563342000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2799737"}},"subtitle":["A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.5403","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}